PTE - Piper Jaffrey

Steadily climbing the validation ladder.

-attends conferences regularly to get the word out
-defends itself specifically, publicly and aggressively against attacks
-very clear and transparent paths forward
-efficacy results are easy to measure
-revenue in play so another easy way to measure
-world renowned medical professionals on staff
-world renowned unaffiliated medical professionals speaking up favorably
-analyst coverage sprouting
-bucking the current black hole like gravitational downward pull of the market
-in a complex busy hospital, it's a simple all inclusive kit in a box sitting on the hospital shelf ready to deploy superior technology.
-a platform with a wave of similarly paradigm shifting tech (like SkinTe) rapidly moving up the pipeline.

SkinTE™ was designed and developed to treat a full spectrum of defects and conditions of

the skin in a manner which truly promotes and utilizes the concept of self regeneration

early on in the healing process —Where Self Regenerates Self

Conditions treated with Skin TE

-Replacement of Prior Skin Grafts
-Acute Surgical
Reconstruction
-Acute Wound Treatment 
-Chronic Wound
Treatment
-Acute Burn Treatment
-Post-Burn
 Reconstruction
-Scar and Contracture Revision
-Keloid and
 Hypertrophic Scar Revision
-Subacute Burn and Wound
 Reconstruction
-Coverage and/or Replacement of Skin
 Substitute
-Failed Skin Graft Replacement
-Failed Flaps
 Coverage
-Soft Tissue Coverage in Infected Defects

-Epidermolysis Bullosa


Used in both Adult and Pediatric Patients in a Variety of Clinical Settings

Deployment in Additional Separate Wounds within Return Patients

Crusher

Piper's comments from 12/20/2018

thefly.com/landingPageNews.php?id=2839657&headline=pte-polarityte-initiated-with-an-overweight-at-piper-jaffray

PolarityTE initiated with an Overweight at Piper Jaffray Piper Jaffray analyst Tyler Van Buren started PolarityTE with an Overweight rating and $30 price target. The company has developed an "incredibly innovative" technological process to expand and regenerate a patient's tissue that has been successfully applied to SkinTE, which is currently launching, and OsteoTE which is expected to launch next year, Van Buren tells investors in a research note. The analyst says key opinion leaders he's spoken to have had a near 100% success rate thus far and feedback has been "great." As such, he has a high level of confidence in the product and assumes a "conservative" $300M in risk-adjusted sales by 2025.